Share Twitter LinkedIn Facebook Email C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses Should MRD Negativity Be The Goal For Every Patient at Lymphoma & Myeloma on October 18, 2018.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read